Contents

14 Pertussis (whooping cough)

References

  1. Cowling BJ, Lau MS, Ho LM, et al. 2010. The effective reproduction number of pandemic influenza: prospective estimation. Epidemiology 21(6): 842–6.
  2. McGovern MC, Smith MB. 2004. Causes of apparent life threatening events in infants: a systematic review. Archives of Disease in Childhood 89(11): 1043–8.
  3. Harnden A, Grant C, Harrison T, et al. 2006. Whooping cough in school age children with persistent cough: prospective cohort study in primary care. British Medical Journal 333:174–7.
  4. Wirsing von Konig CH, Halperin S, Riffelmann M, et al. 2002. Pertussis of adults and infants. The Lancet Infectious Diseases 2(12): 744–50.
  5. Wirsing von Konig CH, Postels Multani S, Bock HL, et al. 1995. Pertussis in adults: frequency of transmission after household exposure. The Lancet 346(8986): 1326–9.
  6. Robertson PW, Goldberg H, Jarvie BH, et al. 1987. Bordetella pertussis infection: a cause of persistent cough in adults. Medical Journal of Australia 146(10): 522–5.
  7. Senzilet LD, Halperin SA, Spika JS, et al. 2001. Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clinical Infectious Diseases 32(12): 191–7.
  8. Gilberg S, Njamkepo E, Du Chatelet IP, et al. 2002. Evidence of Bordetella pertussis infection in adults presenting with persistent cough in a French area with very high whole-cell vaccine coverage. Journal of Infectious Diseases 186(3): 415–18.
  9. Schmitt-Grohe S, Cherry JD, Heininger U, et al. 1995. Pertussis in German adults. Clinical Infectious Diseases 21(4): 860–6.
  10. Philipson K, Goodyear-Smith F, Grant C, et al. 2013. When is acute persistent cough in school-age children and adults whooping cough? British Journal of General Practice 63(613). DOI: 10.3399/bjgp13X670705 (accessed 21 October 2013).
  11. Surridge J, Segedin E, Grant C. 2007. Pertussis requiring intensive care. Archives of Disease in Childhood 92(11): 970–5.
  12. Cherry JD. 2005. The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics 115(5): 1422–7.
  13. Gordon JE, Aycock WL. 1951. Whooping cough and its epidemiological anomalies. American Journal of Medical Sciences 222(3): 333–61.
  14. Haberling DL, Holman RC, Paddock CD, et al. 2009. Infant and maternal risk factors for pertussis-related infant mortality in the United States, 1999 to 2004. Pediatric Infectious Disease Journal 28(3): 194–8.
  15. Van Buynder PG, Owen D, Vurdien JE, et al. 1999. Bordetella pertussis surveillance in England and Wales: 1995–7. Epidemiology & Infection 123(3): 403–11.
  16. Crowcroft NS, Andrews N, Rooney C, et al. 2002. Deaths from pertussis are underestimated in England. Archives of Disease in Childhood 86(5): 336–8.
  17. Sutter RW, Cochi SL. 1992. Pertussis hospitalizations and mortality in the United States, 1985–1988: evaluation of the completeness of national reporting. Journal of the American Medical Association 267(3): 386–91.
  18. Shaikh R, Guris D, Strebel PM, et al. 1998. Underreporting of pertussis deaths in the United States: need for improved surveillance. Pediatrics 101(2): 323.
  19. Wortis N, Strebel PM, Wharton M, et al. 1996. Pertussis deaths: report of 23 cases in the United States, 1992 and 1993. Pediatrics 97(5): 607–12.
  20. Williams GD, Matthews NT, Choong RK, et al. 1998. Infant pertussis deaths in New South Wales 1996–1997. Medical Journal of Australia 168(6): 281–3.
  21. Halasa NB, Barr FE, Johnson JE, et al. 2003. Fatal pulmonary hypertension associated with pertussis in infants: does extracorporeal membrane oxygenation have a role? Pediatrics 112(6 Pt1): 1274–8.
  22. Mikelova LK, Halperin SA, Scheifele D, et al. 2003. Predictors of death in infants hospitalized with pertussis: a case-control study of 16 pertussis deaths in Canada. Journal of Pediatrics 143(5): 576–81.
  23. Joo I. 1991. Epidemiology of pertussis in Hungary. Developments in Biological Standardization 73: 357–9.
  24. Finger H, Wirsing von Konig CH, Tacken A, et al. 1991. The epidemiological situation of pertussis in the Federal Republic of Germany. Developments in Biological Standardization 73: 343–55.
  25. Miller E, Vurdien JE, White JM. 1992. The epidemiology of pertussis in England and Wales. Communicable Disease Report: CDR Review 2(13): R152–154.
  26. White JM, Fairley CK, Owen D, et al. 1996. The effect of an accelerated immunisation schedule on pertussis in England and Wales. Communicable Disease Report: CDR Review 6(6): R86–91.
  27. Romanus V, Jonsell R, Bergquist SO. 1987. Pertussis in Sweden after the cessation of general immunization in 1979. Pediatric Infectious Disease Journal 6(4): 365–71.
  28. Noble GR, Bernier RH, Esber EC, et al. 1987. Acellular and whole-cell pertussis vaccines in Japan: report of a visit by US scientists. Journal of the American Medical Association 257(10): 1351–6.
  29. Kimura M, Kuno-Sakai H. 1990. Developments in pertussis immunisation in Japan. The Lancet 336(8706): 30–2.
  30. Provenzano RW, Wetterlow LH, Sullivan CL. 1959. Pertussis immunization in pediatric practice and in public health. New England Journal of Medicine 261(10): 473–8.
  31. Farizo KM, Cochi SL, Zell ER, et al. 1992. Epidemiological features of pertussis in the United States, 1980–1989. Clinical Infectious Diseases 14(3): 708–19.
  32. Guris D, Strebel PM, Bardenheier B, et al. 1999. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990–1996. Clinical Infectious Diseases 28(6): 1230–7.
  33. Ranganathan S, Tasker R, Booy R, et al. 1999. Pertussis is increasing in unimmunised infants: is a change in policy needed? Archives of Disease in Childhood 80(3): 297–9.
  34. Tanaka M, Vitek CR, Pascual FB, et al. 2003. Trends in pertussis among infants in the United States, 1980–1999. Journal of the American Medical Association 90(22): 2968–75.
  35. Crowcroft NS, Pebody RG. 2006. Recent developments in pertussis. The Lancet 367(9526): 1926–36.
  36. Broutin H, Guegan JF, Elguero E, et al. 2005. Large-scale comparative analysis of pertussis population dynamics: periodicity, synchrony, and impact of vaccination. American Journal of Epidemiology 161(12): 1159–67.
  37. Institute of Environmental Science and Research Ltd. 2013. Notifiable and Other Diseases in New Zealand: Annual report 2012. URL: https://surv.esr.cri.nz/PDF_surveillance/AnnualRpt/AnnualSurv/2012/2012AnnualSurvRpt.pdf (accessed 19 August 2013).
  38. Institute of Environmental Science and Research Ltd. 2013. Pertussis Report: Oct–Dec 2013. URL: https://surv.esr.cri.nz/PDF_surveillance/PertussisRpt/2013/PertussisreportOct-Dec2013.pdf (accessed 18 January 2014).
  39. Grant C. 2012. Recent indication of progress in pertussis hospitalisation rates in NZ. Australian and New Zealand Journal of Public Health 36(4): 398.
  40. Elliott E, McIntyre P, Ridley G, et al. 2004. National study of infants hospitalized with pertussis in the acellular vaccine era. Pediatric Infectious Disease Journal 23(3): 246–52.
  41. Cortese MM, Baughman AL, Zhang R, et al. 2008. Pertussis hospitalizations among infants in the United States, 1993 to 2004. Pediatrics 121(3): 484–92.
  42. Craig E, Adams J, Oben G, et al. 2013. The Health Status of Children and Young People in New Zealand. URL: http://dnmeds.otago.ac.nz/departments/womens/paediatrics/research/nzcyes/pdf/Rpt2011_NZReport.pdf (accessed 21 July 2013).
  43. Dhillon S. 2010. DTPa-HBV-IPV/Hib vaccine (Infanrix hexa): a review of its use as primary and booster vaccination. Drugs 70(8): 1021–58.
  44. Zepp F, Schmitt HJ, Cleerbout J, et al. 2009. Review of 8 years of experience with Infanrix hexa (DTPa-HBV-IPV/Hib hexavalent vaccine). Expert Review of Drugs 8(6): 663–78.
  45. Greco D, Salmaso S, Mastrantonio P, et al. 1996. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. New England Journal of Medicine 334(6): 341–8.
  46. Edwards KM, Decker MD. 2013. Pertussis vaccines. In: Plotkin SA, Orenstein W, Offit PA (eds). Vaccines (6th edition): Elsevier Saunders.
  47. Gustafsson L, Hessel L, Storsaeter J, et al. 2006. Long-term follow up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates need for a booster dose at 5 to 7 years of age. Pediatrics 118(3). DOI: 10.1542/peds.2005-2746 (accessed 15 December 2013).
  48. Tartof SY, Lewis M, Kenyon C, et al. 2013. Waning immunity to pertussis following 5 doses of DTaP. Pediatrics 131(4). DOI: 10.1542/peds.2012-1928 (accessed 21 July 2013).
  49. Witt MA, Arias L, Katz PH, et al. 2013. Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort. Clinical Infectious Diseases 56(9): 1248–54.
  50. Ward JI, Cherry JD, Chang SJ, et al. 2005. Efficacy of an acellular pertussis vaccine among adolescents and adults. New England Journal of Medicine 353(15): 1555–63.
  51. McIntyre P, Burgess MA, Egan A, et al. 2009. Booster vaccination of adults with reduced-antigen-content diphtheria, tetanus and pertussis vaccine: immunogenicity 5 years post-vaccination. Vaccine 27(7): 1062–6.
  52. Ministry of Health. 2012. National Guidelines for Vaccine Storage and Distribution. URL: www.health.govt.nz/publication/national-guidelines-vaccine-storage-and-distribution-2012
  53. GlaxoSmithKline NZ Ltd. 2014. Infanrix-hexa New Zealand Data Sheet. URL: http://www.medsafe.govt.nz/profs/datasheet/I/Infanrixhexainj.pdf (accessed 22 May 2015).
  54. Knuf M, Habermehl P, Cimino C, et al. 2006. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants. Vaccine 24(22):4727–36.
  55. Olivier C, Belohradsky B, Stojanov S, et al. 2008. Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa–IPV–HBV–Hib combination vaccine in healthy infants. Vaccine 26(25): 3142–52.
  56. Kieninger D, Kueper K, Steul K, et al. 2010. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine 28(25): 4192–203.
  57. Esposito S, Tansey S, Thompson A, et al. 2010. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clinical and Vaccine Immunology (17)6: 1017–26.
  58. Beytout J, Launay O, Guiso N, et al. 2009. Safety of Tdap-IPV given 1 month after Td-IPV booster in healthy young adults: a placebo controlled trial. Human Vaccines and Immunotherapeutics 5(5): 315–21.
  59. Talbot EA, Brown KH, Kirkland KB, et al. 2010. The safety of immunizing with tetanus-diphtheria-acellular pertussis vaccine (Tdap) less than 2 years following previous tetanus vaccination: experience during a mass vaccination campaign of health care personnel during a respiratory illness outbreak. Vaccine 28(50): 8001–7.
  60. Centers for Disease Control and Prevention. 2011. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. Morbidity and Mortality Weekly Report 60(1). URL: www.cdc.gov/mmwr/pdf/wk/mm6001.pdf (accessed 21 October 2013).
  61. Centers for Disease Control and Prevention. 2013. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women – Advisory Committee on Immunization Practices (ACIP), 2012. Morbidity and Mortality Weekly Report 62(7). URL: www.cdc.gov/mmwr/preview/mmwrhtml/mm6207a4.htm (accessed 22 October 2013).
  62. Lee J, Robinson JL, Spady DW. 2006. Frequency of apnea, bradycardia, and desaturations following first diphtheria-tetanus-pertussis-inactivated polio-Haemophilus influenzae type B immunization in hospitalized preterm infants. BMC Pediatrics 20(6). DOI: 10.1186/1471-2431-6-20 (accessed 11 October 2013).
  63. Howson CP, Fineberg HV. 1992. Adverse events following pertussis and rubella vaccines: summary of a report of the Institute of Medicine. Journal of the American Medical Association 267(3): 392–6.
  64. Walker AM, Jick H, Perera DR, et al. 1988. Neurologic events following diphtheria-tetanus-pertussis immunization. Pediatrics 81(3): 345–9.
  65. Griffin MR, Ray WA, Mortimer EA, et al. 1990. Risk of seizures and encephalopathy after immunization with the diphtheria-tetanus-pertussis vaccine. Journal of the American Medical Association 263(12): 1641–5.
  66. Melchior JC. 1977. Infantile spasms and early immunization against whooping cough: Danish survey from 1970 to 1975. Archives of Disease in Childhood 52(2): 134–7.
  67. Shields WD, Nielsen C, Buch D, et al. 1988. Relationship of pertussis immunization to the onset of neurologic disorders: a retrospective epidemiologic study. Journal of Pediatrics 113(5): 801–5.
  68. Taylor EM, Emery JL. 1982. Immunization and cot deaths. The Lancet 320(8300): 721.
  69. Hoffman HJ, Hunter JC, Damus K, et al. 1987. Diphtheria-tetanus-pertussis immunization and sudden infant death: results of the National Institute of Child Health and Human Development Cooperative Epidemiological Study of Sudden Infant Death Syndrome risk factors. Pediatrics 79(4): 598–611.
  70. Flahault A, Messiah A, Jougla E, et al. 1988. Sudden infant death syndrome and diphtheria/tetanus toxoid/pertussis/poliomyelitis immunisation. The Lancet 331(8585): 582–3.
  71. Mitchell EA, Stewart AW, Clements M. 1995. Immunisation and the sudden infant death syndrome: New Zealand Cot Death Study Group. Archives of Disease in Childhood 73(6): 498–501.
  72. Lyseng-Williamson KA, Dhillon S. 2012. DTPa-HBV-IPV/Hib vaccine (Infanrix hexaTM): a guide to its use in infants. Pediatric Drugs 14(5): 337–43.
  73. Omeñaca F, Garcia-Sicilia J, García-Corbeira P, et al. 2005. Response of preterm newborns to immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio and Haemophilus influenzae type b vaccine: first experiences and solutions to a serious and sensitive issue. Pediatrics 116(6): 1292–98.
  74. Jackson LA, Yu O, Belongia EA, et al. 2009. Frequency of medically attended adverse events following tetanus and diphtheria toxoid vaccine in adolescents and young adults: a Vaccine Safety Datalink study. BMC Infectious Diseases 9(165). DOI: 10.1186/1471-2334-9-165 (accessed 31 January 2013).
  75. Yih WK, Nordin JD, Kulldorff M, et al. 2009. An assessment of the safety of adolescent and adult tetanus-diphtheria-acellular pertussis (Tdap) vaccine, using active surveillance for adverse events in the Vaccine Safety Datalink. Vaccine 27(32): 4257–62.
  76. Moro PL, Yue X, Lewis P, et al. 2011. Adverse events after tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine administered to adults 65 years of age and older reported to the Vaccine Adverse Event Reporting System (VAERS), 2005–2010. Vaccine 29(50): 9404–8.
  77. Zheteyeva YA, Moro PL, Tepper NK, et al. 2012. Adverse event reports after tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines in pregnant women. American Journal of Obstetrics and Gynecology 207(1): 59.e1–7.
  78. Centers for Disease Control and Prevention. 2006. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report 55(RR-3). URL: www.cdc.gov/mmwr/pdf/rr/rr5503.pdf
  79. Baraff LJ, Shields WD, Beckwith L, et al. 1988. Infants and children with convulsions and hypotonic-hyporesponsive episodes following diphtheria-tetanus-pertussis immunization: follow-up evaluation. Pediatrics 81(6): 789–94.
  80. Braun MM, Terracciano G, Salive ME, et al. 1998. Report of a US public health service workshop on hypotonic-hyporesponsive episode (HHE) after pertussis immunization. Pediatrics 102(5): E52.
  81. Hirtz DG, Nelson KB, Ellenberg JH. 1983. Seizures following childhood immunizations. Journal of Pediatrics 102(1): 14–18.
  82. Barlow WE, Davis RL, Glasser JW, et al. 2001. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. New England Journal of Medicine 345(9): 656–61.
  83. Goodwin H, Nash M, Gold M, et al. 1999. Vaccination of children following a previous hypotonic-hyporesponsive episode. Journal of Paediatrics and Child Health 35(6): 549–52.
  84. McIntyre P, Wood N. 2009. Pertussis in early infancy: disease burden and preventive strategies. Current Opinion in Infectious Diseases 22(3): 215–23.
  85. Grant CC, Roberts M, Scragg R, et al. 2003. Delayed immunisation and risk of pertussis in infants: unmatched case-control study. British Medical Journal 326(7394): 852–3.
  86. de Serres G, Shadmani R, Duval B, et al. 2000. Morbidity of pertussis in adolescents and adults. Journal of Infectious Diseases 182(1): 174–9.
  87. Centers for Disease Control and Prevention. 2008. Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report: Recommendations and Reports 57(RR-4). URL: www.cdc.gov/mmwr/PDF/rr/rr5704.pdf
  88. Bonacorsi S, Farnoux C, Bidet P, et al. 2006. Treatment failure of nosocomial pertussis infection in a very-low-birth-weight neonate. Journal of Clinical Microbiology 44(10): 3830–2.
  89. American Academy of Pediatrics. 2012. Pertussis (whooping cough). In: Pickering LK, Baker CJ, Kimberlin DW, et al (eds). Red Book: 2012 report of the Committee on Infectious Diseases: (29th edition). Elk Grove Village, IL: American Academy of Pediatrics.
  90. Wirsing von Konig CH. 2005. Use of antibiotics in the prevention and treatment of pertussis. Pediatric Infectious Disease Journal 24(5 Suppl): S66–68.
  91. Bergquist SO, Bernander S, Dahnsjo H, et al. 1987. Erythromycin in the treatment of pertussis: a study of bacteriologic and clinical effects. Pediatric Infectious Disease Journal 6(5): 458–461. [Published erratum appears in Pediatric Infectious Disease Journal 1987; 6(11): 1035.].
  92. Centers for Disease Control and Prevention. 2000. Guidelines for the Control of Pertussis Outbreaks. URL: www.cdc.gov/pertussis/outbreaks/guide/downloads/chapter-05.pdf
  93. Cooper WO, Ray WA, Griffin MR. 2002. Prenatal prescription of macrolide antibiotics and infantile hypertrophic pyloric stenosis. Obstetrics & Gynecology 100(1): 101–6.
  94. Sorensen HT, Skriver MV, Pedersen L, et al. 2003. Risk of infantile hypertrophic pyloric stenosis after maternal postnatal use of macrolides. Scandinavian Journal of Infectious Diseases 35(2): 104–6.
  95. Maheshwai N. 2007. Are young infants treated with erythromycin at risk for developing hypertrophic pyloric stenosis? Archives of Disease in Childhood 92(3): 271–3.
  96. Centers for Disease Control and Prevention. 1999. Hypertrophic pyloric stenosis in infants following pertussis prophylaxis with erythromycin–Knoxville, Tennessee, 1999. Morbidity and Mortality Weekly Report 48(49). URL: www.cdc.gov/mmwr/PDF/wk/mm4849.pdf
  97. Honein MA, Paulozzi LJ, Himelright IM, et al. 1999. Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromcyin: a case review and cohort study. [Published erratum appears in Lancet 2000; 355(9205): 758.]. The Lancet 354(9196): 2101–5.
  98. Ministry of Health. 2012. Communicable Disease Control Manual 2012. URL: www.health.govt.nz/publication/communicable-disease-control-manual-2012
  99. Centers for Disease Control and Prevention. 2005. Recommended antimicrobial agents for treatment and postexposure prophylaxis of pertussis. Morbidity and Mortality Weekly Report: Recommendations and Reports 54(RR-14). URL: www.cdc.gov/mmwr/pdf/rr/rr5414.pdf
  100. Communicable Diseases Network Australia. 2013. Pertussis: CNDA national guidelines for public health units. URL: www.health.gov.au/internet/main/publishing.nsf/Content/3240888A0EA7E16BCA257BF000191641/$File/pertussis-SoNG-guidelines-March13.pdf (accessed 2 November 2013).